Alpha-cyano-N-(2,5-dibromophenyl)-beta-hydroxybut-2-enamide.

Area of Science:

• Medicinal Chemistry
• Molecular Biology
• Biochemistry

Background:

• Bruton's tyrosine kinase (BTK) is a key regulator in B-cell signaling.
• Dysregulation of BTK is implicated in various B-cell malignancies.
• Targeting BTK offers a therapeutic strategy for leukemia and other B-cell cancers.

Purpose of the Study:

• To introduce LFM-A13 as a novel, potent, and selective inhibitor of Bruton's tyrosine kinase (BTK).
• To characterize the structural and conformational properties of LFM-A13.
• To evaluate LFM-A13 as a potential antileukemic agent.

Main Methods:

• Chemical synthesis and characterization of LFM-A13.
• X-ray crystallography to determine the molecular and crystal structure.
• Conformational analysis based on crystal structure data.

Main Results:

• LFM-A13 (C11H8Br2N2O2) was synthesized and identified as the first BTK-specific tyrosine kinase inhibitor.
• Crystal structure analysis revealed an approximately planar conformation stabilized by intramolecular hydrogen bonding.
• The dihedral angle between the phenyl ring and the N-C-C=C-CH3 plane is 8.2 degrees.
• Crystal packing exhibited intermolecular hydrogen bonds, suggesting potential interactions in biological systems.

Conclusions:

• LFM-A13 represents a significant advancement in targeted cancer therapy, specifically as an antileukemic agent.
• Its unique planar conformation and hydrogen bonding interactions may contribute to its BTK inhibitory activity.
• Further investigation into LFM-A13's therapeutic potential in B-cell malignancies is warranted.